- Home
- PLUS vs ZLAB Comparison
PLUS vs ZLAB Comparison
Compare PLUS & ZLAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLUS
- ZLAB
- Stock Information
- Founded
- PLUS 1990
- ZLAB 2013
- Country
- PLUS United States
- ZLAB China
- Employees
- PLUS N/A
- ZLAB N/A
- Industry
- PLUS Retail: Computer Software & Peripheral Equipment
- ZLAB Biotechnology: Pharmaceutical Preparations
- Sector
- PLUS Technology
- ZLAB Health Care
- Exchange
- PLUS Nasdaq
- ZLAB Nasdaq
- Market Cap
- PLUS 1.9B
- ZLAB 3.6B
- IPO Year
- PLUS 1996
- ZLAB 2017
- Fundamental
- Price
- PLUS $68.86
- ZLAB $35.19
- Analyst Decision
- PLUS
- ZLAB Buy
- Analyst Count
- PLUS 0
- ZLAB 5
- Target Price
- PLUS N/A
- ZLAB $54.28
- AVG Volume (30 Days)
- PLUS 226.9K
- ZLAB 689.4K
- Earning Date
- PLUS 08-05-2025
- ZLAB 08-07-2025
- Dividend Yield
- PLUS N/A
- ZLAB N/A
- EPS Growth
- PLUS N/A
- ZLAB N/A
- EPS
- PLUS 4.05
- ZLAB N/A
- Revenue
- PLUS $2,068,789,000.00
- ZLAB $418,326,000.00
- Revenue This Year
- PLUS $3.88
- ZLAB $44.07
- Revenue Next Year
- PLUS $2.84
- ZLAB $49.13
- P/E Ratio
- PLUS $17.01
- ZLAB N/A
- Revenue Growth
- PLUS N/A
- ZLAB 43.72
- 52 Week Low
- PLUS $53.83
- ZLAB $16.01
- 52 Week High
- PLUS $106.98
- ZLAB $44.34
- Technical
- Relative Strength Index (RSI)
- PLUS 48.07
- ZLAB 49.90
- Support Level
- PLUS $69.25
- ZLAB $32.31
- Resistance Level
- PLUS $72.37
- ZLAB $35.72
- Average True Range (ATR)
- PLUS 1.88
- ZLAB 1.10
- MACD
- PLUS -0.43
- ZLAB -0.34
- Stochastic Oscillator
- PLUS 17.40
- ZLAB 60.17
About PLUS ePlus inc.
ePlus Inc is a provider of technology solutions across the IT spectrum, spanning security, cloud, data center, networking, collaboration, AI, service provider, and critical infrastructure, and emerging solutions, to domestic and foreign organizations across all industry segments. Its solutions leverage a broad range of professional, consultative, and managed services across the technology spectrum. The company possesses top-level engineering certifications with a broad range of IT technologies that enable the company to offer multi-vendor IT solutions that are optimized for each of its customers' specific requirements. It also offers a wide portfolio of technology and other capital asset financing solutions to customers across commercial and government enterprises, designing programs.
About ZLAB Zai Lab Limited
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. The pipeline of proprietary drug candidates of the company includes ZL-1218 (CCR8) Solid Tumors, ZL-1310 (DLL3 ADC) ES-SCLC Other NECs, ZL-6301 (ROR1 ADC) Solid Tumors, ZL 6201 (LRRC15 ADC) Solid Tumors.